Engineered Biomaterials for Cancer Immunotherapy

Overview

Journal MedComm (2020)

Specialty Health Services

Date 2021 Nov 12

PMID 34766108

Citations 25

Authors

Lulu Cai

Jialu Xu

Zhenglin Yang

Rongsheng Tong

Ziliang Dong

Chao Wang

Kam W Leong

Affiliations

Soon will be listed here.

Abstract

Although cancer immunotherapy is showing tremendous promise and has progressed to the clinic, it has only achieved sporadic efficacy, with only a fraction of patients benefitting from the therapy and with undesirable side effects due to poor selectivity and high doses. Localized delivery of immunomodulators to activate anticancer immunity in situ avoids overactivation of the systemic immune system and reduces side effects. Engineered biomaterials-implantable, injectable, or transdermal-fabricated into drug delivery devices are critical components for the development of localized cancer immunotherapies. In this review, we briefly summarize progress in the application of engineered biomaterials to the localized delivery of cancer immunotherapy.

Citing Articles

Immune Cell Homing Hydrogels for Cancer Immunotherapy.

Han J, Wang H Methods Mol Biol. 2025; 2902:107-116.

PMID: 40029598 DOI: 10.1007/978-1-0716-4402-7_6.

Research Progress on the Application of Natural Medicines in Biomaterial Coatings.

Wang Y, Duan H, Zhang Z, Chen L, Li J Materials (Basel). 2024; 17(22).

PMID: 39597430 PMC: 11595593. DOI: 10.3390/ma17225607.

Comprehensive insights into glioblastoma multiforme: drug delivery challenges and multimodal treatment strategies.

Dhiman A, Rana D, Benival D, Garkhal K Ther Deliv. 2024; 16(1):87-115.

PMID: 39445563 PMC: 11703381. DOI: 10.1080/20415990.2024.2415281.

Overcoming neutrophil-induced immunosuppression in postoperative cancer therapy: Combined sialic acid-modified liposomes with scaffold-based vaccines.

Li C, Wang L, Zhang K, Wang Z, Li Z, Li Z Asian J Pharm Sci. 2024; 19(2):100906.

PMID: 38595333 PMC: 11002593. DOI: 10.1016/j.ajps.2024.100906.

Biomaterial-Based Responsive Nanomedicines for Targeting Solid Tumor Microenvironments.

Avgoustakis K, Angelopoulou A Pharmaceutics. 2024; 16(2).

PMID: 38399240 PMC: 10892652. DOI: 10.3390/pharmaceutics16020179.

References

Urdinguio R, Fernandez A, Moncada-Pazos A, Huidobro C, Rodriguez R, Ferrero C . Immune-dependent and independent antitumor activity of GM-CSF aberrantly expressed by mouse and human colorectal tumors. Cancer Res. 2012; 73(1):395-405. DOI: 10.1158/0008-5472.CAN-12-0806. View

Ali O, Huebsch N, Cao L, Dranoff G, Mooney D . Infection-mimicking materials to program dendritic cells in situ. Nat Mater. 2009; 8(2):151-8. PMC: 2684978. DOI: 10.1038/nmat2357. View

Verdegaal E, de Miranda N, Visser M, Harryvan T, van Buuren M, Andersen R . Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 2016; 536(7614):91-5. DOI: 10.1038/nature18945. View

Ye Y, Yu J, Wen D, Kahkoska A, Gu Z . Polymeric microneedles for transdermal protein delivery. Adv Drug Deliv Rev. 2018; 127:106-118. PMC: 6020694. DOI: 10.1016/j.addr.2018.01.015. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Eisenstein M . Something new under the skin. Nat Biotechnol. 2011; 29(2):107-9. DOI: 10.1038/nbt.1768. View

Moslehi J, Salem J, Sosman J, Lebrun-Vignes B, Johnson D . Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391(10124):933. PMC: 6668330. DOI: 10.1016/S0140-6736(18)30533-6. View

Simoes M, Sousa J, Pais A . Skin cancer and new treatment perspectives: a review. Cancer Lett. 2014; 357(1):8-42. DOI: 10.1016/j.canlet.2014.11.001. View

Wang C, Ye Y, Hu Q, Bellotti A, Gu Z . Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. Adv Mater. 2017; 29(29). DOI: 10.1002/adma.201606036. View

10.

Chinembiri T, du Plessis L, Gerber M, Hamman J, Du Plessis J . Review of natural compounds for potential skin cancer treatment. Molecules. 2014; 19(8):11679-721. PMC: 6271439. DOI: 10.3390/molecules190811679. View

11.

Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H . In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2018; 14(1):89-97. DOI: 10.1038/s41565-018-0319-4. View

12.

Ishihara J, Fukunaga K, Ishihara A, Larsson H, Potin L, Hosseinchi P . Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. Sci Transl Med. 2017; 9(415). DOI: 10.1126/scitranslmed.aan0401. View

13.

Wang T, Wang D, Yu H, Feng B, Zhou F, Zhang H . A cancer vaccine-mediated postoperative immunotherapy for recurrent and metastatic tumors. Nat Commun. 2018; 9(1):1532. PMC: 5906566. DOI: 10.1038/s41467-018-03915-4. View

14.

Stephan S, Taber A, Jileaeva I, Pegues E, Sentman C, Stephan M . Biopolymer implants enhance the efficacy of adoptive T-cell therapy. Nat Biotechnol. 2014; 33(1):97-101. PMC: 4289408. DOI: 10.1038/nbt.3104. View

15.

Prausnitz M . Engineering Microneedle Patches for Vaccination and Drug Delivery to Skin. Annu Rev Chem Biomol Eng. 2017; 8:177-200. DOI: 10.1146/annurev-chembioeng-060816-101514. View

16.

Lei K, Tang L . Surgery-free injectable macroscale biomaterials for local cancer immunotherapy. Biomater Sci. 2019; 7(3):733-749. DOI: 10.1039/c8bm01470a. View

17.

Ribas A . Releasing the Brakes on Cancer Immunotherapy. N Engl J Med. 2015; 373(16):1490-2. DOI: 10.1056/NEJMp1510079. View

18.

Ye Y, Wang C, Zhang X, Hu Q, Zhang Y, Liu Q . A melanin-mediated cancer immunotherapy patch. Sci Immunol. 2017; 2(17). DOI: 10.1126/sciimmunol.aan5692. View

19.

Fang R, Kroll A, Zhang L . Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small. 2015; 11(41):5483-96. PMC: 4641138. DOI: 10.1002/smll.201501284. View

20.

Weber J, Mule J . Cancer immunotherapy meets biomaterials. Nat Biotechnol. 2015; 33(1):44-5. DOI: 10.1038/nbt.3119. View